Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

NCT05512208 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT05512208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Recruiting
Start date
February 6, 2023
Completion date
December 31, 2029
Enrollment
55 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrioid cancer, high grade serous ovarian cancer, mucinous ovarian cancer, solid tumor